Claims
- 1. A method of protecting a primate against HIV-1 infection comprising intranasal or intramuscular administration to said primate of an intranasal or intramuscular dosage of a recombinant adenovirus having a deletion in the E3 gene and an expression cassette containing a major late promoter, a tripartite leader sequence, part or all of the HIV-1 gp160 sequence and a polyadenylation signal sequence, said cassette being inserted into said recombinant adenovirus between the E4 promoter and the inverted terminal repeat of said recombinant adenovirus.
- 2. The method of claim 1 wherein said intranasal or intramuscular administration of recombinant adenovirus is followed by one or more intranasal or intramuscluar booster administrations of said recombinant adenovirus.
- 3. The method of claim 2 wherein said adenovirus is a serotype 4, 5 or 7 serotype adenovirus.
- 4. The method of claim 3 wherein said expression cassette additionally comprises part of all of the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 sequence and before the polyadenylation signal sequence.
- 5. The method of claim 4 wherein said HIV-1 gp160 sequence is the MN strain gp160 sequence or the LAV strain gp160 sequence.
- 6. The method of claim 4 wherein said HIV-1 gp160 sequence is replaced by a sequence encoding the gag-pro region of HIV-1.
- 7. The method of claim 2 wherein said one or more intranasal or intramuscular booster administrations of said adenovirus are followed by an intramuscular injection of at least one booster immunization with an HIV-1 subunit antigen preparation.
- 8. The method of claim 7 wherein said HIV-1 subunit antigen preparation contains an HIV-1 gag and/or env polypeptide sequence.
- 9. The method of claim 1 wherein said intranasal dosage administered is in the range of 1×107 pfu of virus.
- 10. The method of claim 1 wherein said intramuscular dosage administered is in the range of 1×107 to 2×109 pfu of virus.
- 11. The method of claim 9 wherein said intranasal booster is administered in a dosage in the range of 1×107 to 1×108 pfu of virus.
- 12. The method of claim 10 wherein said intramuscular booster is administered in a dosage in the range of 1×1010 to 8×1010 pfu of virus.
- 13. The method of claim 8 wherein said subunit antigen preparation contains between 200 μg and 0.5 mg of HIV-1 polypeptide.
- 14. A method of protecting a primate against HIV-1 infection comprising the steps of (i) intranasal or intramuscular administration to said primate of an intranasal or intramuscular dosage of a recombinant adenovirus serotype 4, 5 or 7 having a deletion in the E3 gene and an expression cassette containing a major late promoter, a tripartite leader sequence, part or all of the HIV-1 gp160 sequence, part of all of the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 sequence and a polyadenylation signal sequence, said cassette being inserted into said recombinant adenovirus between the E4 promoter and the inverted terminal repeat of said recombinant adenovirus; and (ii), followed by one or more intranasal or intramuscular booster administrations of said recombinant adenovirus.
- 15. The method of claim 14 wherein said primate is a human.
- 16. The method of claim 15 wherein said HIV-1 gp 160 sequence is replaced by a sequence encoding the gag-pro region of HIV-1.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation in part of Ser. No. 08/276,289, filed Jul. 20, 1994, which is a continuation in part of Ser. No. 08/105,232, filed Aug. 11, 1993, which is a continuation-in-part of Ser. No. 07/926,491, filed Aug. 7, 1992.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09457421 |
Dec 1999 |
US |
Child |
10794876 |
Mar 2004 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
08276289 |
Jul 1994 |
US |
Child |
09457421 |
Dec 1999 |
US |
Parent |
08105232 |
Aug 1993 |
US |
Child |
08276289 |
Jul 1994 |
US |
Parent |
07926491 |
Aug 1992 |
US |
Child |
08105232 |
Aug 1993 |
US |